#612020
Table of Contents
A number sign (#) is used with this entry because of evidence that spastic paraplegia-39 (SPG39) is caused by homozygous or compound heterozygous mutation in the PNPLA6 gene (603197) on chromosome 19p13.
The form of motor neuron disease designated spastic paraplegia-39 (SPG39) by Rainier et al. (2008) is an autosomal recessive progressive spastic paraplegia associated with distal upper and lower extremity wasting.
For a general phenotypic description and a discussion of genetic heterogeneity of autosomal recessive spastic paraplegia, see 270800.
Rainier et al. (2008) reported a consanguineous family of Ashkenazi Jewish ancestry and an unrelated nonconsanguineous family of northern European ancestry in which affected subjects developed childhood onset of insidiously progressive lower extremity spastic weakness and progressive wasting of distal upper and lower extremity muscles. Electrophysiologic studies were consistent with a motor axonopathy affecting upper and lower limbs. Magnetic resonance imaging demonstrated spinal cord atrophy, particularly in the thoracic region. The affected phenotype in each family conformed both to organophosphorous (OP) compound-induced delayed neuropathy (OPIDN) and to Troyer syndrome (275900), an autosomal recessive hereditary spastic paraplegia associated with distal muscle wasting. However, additional neurologic and systemic abnormalities seen in Troyer syndrome, including delayed milestone acquisition, skeletal abnormalities, and cerebellar, extrapyramidal, and cognitive impairment, were not observed.
Synofzik et al. (2014) reported a 56-year-old German woman with SPG39 who developed spasticity with hyperreflexia and extensor plantar responses at age 20 years. She had no other abnormalities and brain imaging was normal. A 48-year-old unrelated German man developed spastic gait ataxia at age 4 years. He had hyperreflexia, extensor plantar responses, and cerebellar atrophy on brain imaging. The phenotypes of these patients illustrate the clinical variability that is associated with SPG39.
The transmission pattern of SPG39 in the families reported by Rainier et al. (2008) was consistent with autosomal recessive inheritance.
Rainier et al. (2008) performed genomewide linkage analysis in a large consanguineous Ashkenazi family and in a second nonconsanguineous family. An extended linkage haplotype that spanned 22 cM between D19S565 and D19S884 on chromosome 19p13 was defined in the consanguineous family; in the nonconsanguineous family the same markers also resulted in haplotype sharing in affected subjects, consistent with genetic linkage of the region.
In affected members of 2 families with motor neuron disease, Rainier et al. (2008) detected homozygosity or compound heterozygosity for mutations in the NTE gene. Affected subjects in the consanguineous kindred were homozygous for a disease-specific NTE mutation, c.3034A-G, that disrupted an interspecies-conserved residue in NTE's catalytic domain (M1012V; 603197.0001). Affected subjects in the nonconsanguineous family were compound heterozygotes: 1 allele carried a c.2669G-A mutation that disrupted an interspecies-conserved residue in NTE's catalytic domain (R890H; 603197.0002), and the other allele had an insertion that caused frameshift and protein truncation (603197.0003).
In 2 unrelated German patients with SPG39, Synofzik et al. (2014) identified compound heterozygous mutations in the PNPLA6 gene (see, e.g., 603197.0009 and 603197.0010).
Rainier, S., Bui, M., Mark, E., Thomas, D., Tokarz, D., Ming, L., Delaney, C., Richardson, R. J., Albers, J. W., Matsunami, N., Stevens, J., Coon, H., Leppert, M., Fink, J. K. Neuropathy target esterase gene mutations cause motor neuron disease. Am. J. Hum. Genet. 82: 780-785, 2008. [PubMed: 18313024, images, related citations] [Full Text]
Synofzik, M., Gonzalez, M. A., Lourenco, C. M., Coutelier, M., Haack, T. B., Rebelo, A., Hannequin, D., Strom, T. M., Prokisch, H., Kernstock, C., Durr, A., Schols, L., Lima-Martinez, M. M., Farooq, A., Schule, R., Stevanin, G., Marques, W., Jr., Zuchner, S. PNPLA6 mutations cause Boucher-Neuhauser and Gordon Holmes syndromes as part of a broad neurodegenerative spectrum. Brain 137: 69-77, 2014. [PubMed: 24355708, images, related citations] [Full Text]
Alternative titles; symbols
SNOMEDCT: 719103009; ORPHA: 139480; DO: 0110790;
| Location | Phenotype |
Phenotype MIM number |
Inheritance |
Phenotype mapping key |
Gene/Locus |
Gene/Locus MIM number |
|---|---|---|---|---|---|---|
| 19p13.2 | Spastic paraplegia 39, autosomal recessive | 612020 | Autosomal recessive | 3 | PNPLA6 | 603197 |
A number sign (#) is used with this entry because of evidence that spastic paraplegia-39 (SPG39) is caused by homozygous or compound heterozygous mutation in the PNPLA6 gene (603197) on chromosome 19p13.
The form of motor neuron disease designated spastic paraplegia-39 (SPG39) by Rainier et al. (2008) is an autosomal recessive progressive spastic paraplegia associated with distal upper and lower extremity wasting.
For a general phenotypic description and a discussion of genetic heterogeneity of autosomal recessive spastic paraplegia, see 270800.
Rainier et al. (2008) reported a consanguineous family of Ashkenazi Jewish ancestry and an unrelated nonconsanguineous family of northern European ancestry in which affected subjects developed childhood onset of insidiously progressive lower extremity spastic weakness and progressive wasting of distal upper and lower extremity muscles. Electrophysiologic studies were consistent with a motor axonopathy affecting upper and lower limbs. Magnetic resonance imaging demonstrated spinal cord atrophy, particularly in the thoracic region. The affected phenotype in each family conformed both to organophosphorous (OP) compound-induced delayed neuropathy (OPIDN) and to Troyer syndrome (275900), an autosomal recessive hereditary spastic paraplegia associated with distal muscle wasting. However, additional neurologic and systemic abnormalities seen in Troyer syndrome, including delayed milestone acquisition, skeletal abnormalities, and cerebellar, extrapyramidal, and cognitive impairment, were not observed.
Synofzik et al. (2014) reported a 56-year-old German woman with SPG39 who developed spasticity with hyperreflexia and extensor plantar responses at age 20 years. She had no other abnormalities and brain imaging was normal. A 48-year-old unrelated German man developed spastic gait ataxia at age 4 years. He had hyperreflexia, extensor plantar responses, and cerebellar atrophy on brain imaging. The phenotypes of these patients illustrate the clinical variability that is associated with SPG39.
The transmission pattern of SPG39 in the families reported by Rainier et al. (2008) was consistent with autosomal recessive inheritance.
Rainier et al. (2008) performed genomewide linkage analysis in a large consanguineous Ashkenazi family and in a second nonconsanguineous family. An extended linkage haplotype that spanned 22 cM between D19S565 and D19S884 on chromosome 19p13 was defined in the consanguineous family; in the nonconsanguineous family the same markers also resulted in haplotype sharing in affected subjects, consistent with genetic linkage of the region.
In affected members of 2 families with motor neuron disease, Rainier et al. (2008) detected homozygosity or compound heterozygosity for mutations in the NTE gene. Affected subjects in the consanguineous kindred were homozygous for a disease-specific NTE mutation, c.3034A-G, that disrupted an interspecies-conserved residue in NTE's catalytic domain (M1012V; 603197.0001). Affected subjects in the nonconsanguineous family were compound heterozygotes: 1 allele carried a c.2669G-A mutation that disrupted an interspecies-conserved residue in NTE's catalytic domain (R890H; 603197.0002), and the other allele had an insertion that caused frameshift and protein truncation (603197.0003).
In 2 unrelated German patients with SPG39, Synofzik et al. (2014) identified compound heterozygous mutations in the PNPLA6 gene (see, e.g., 603197.0009 and 603197.0010).
Rainier, S., Bui, M., Mark, E., Thomas, D., Tokarz, D., Ming, L., Delaney, C., Richardson, R. J., Albers, J. W., Matsunami, N., Stevens, J., Coon, H., Leppert, M., Fink, J. K. Neuropathy target esterase gene mutations cause motor neuron disease. Am. J. Hum. Genet. 82: 780-785, 2008. [PubMed: 18313024] [Full Text: https://doi.org/10.1016/j.ajhg.2007.12.018]
Synofzik, M., Gonzalez, M. A., Lourenco, C. M., Coutelier, M., Haack, T. B., Rebelo, A., Hannequin, D., Strom, T. M., Prokisch, H., Kernstock, C., Durr, A., Schols, L., Lima-Martinez, M. M., Farooq, A., Schule, R., Stevanin, G., Marques, W., Jr., Zuchner, S. PNPLA6 mutations cause Boucher-Neuhauser and Gordon Holmes syndromes as part of a broad neurodegenerative spectrum. Brain 137: 69-77, 2014. [PubMed: 24355708] [Full Text: https://doi.org/10.1093/brain/awt326]
Dear OMIM User,
To ensure long-term funding for the OMIM project, we have diversified our revenue stream. We are determined to keep this website freely accessible. Unfortunately, it is not free to produce. Expert curators review the literature and organize it to facilitate your work. Over 90% of the OMIM's operating expenses go to salary support for MD and PhD science writers and biocurators. Please join your colleagues by making a donation now and again in the future. Donations are an important component of our efforts to ensure long-term funding to provide you the information that you need at your fingertips.
Thank you in advance for your generous support,
Ada Hamosh, MD, MPH
Scientific Director, OMIM